Yesterday it was reported that the EVP & GC of Exelixis (EXEL), Jeffrey Hessekiel, exercised options to sell 75,000 EXEL shares at $1.70 a share, for a total transaction value of $1.58M.
In addition to Jeffrey Hessekiel, 4 other EXEL executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Exelixis’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $240 million and quarterly net profit of $79.04 million. In comparison, last year the company earned revenue of $186 million and had a net profit of $87.49 million. The company has a one-year high of $25.31 and a one-year low of $13.42. EXEL’s market cap is $6.59B and the company has a P/E ratio of 10.62.
In the last 30 days, insiders have sold $3.01M worth of EXEL shares and purchased $359K worth of EXEL shares. The insider sentiment on Exelixis has been positive according to 94 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic.
